MicroGard™ II PFT Filter
MicroGard II filters provide an easy way to help ensure protection from cross-contamination which keeps both the patient and operator safe without compromising on system performance.
MicroGard II filters are used with Vyntus™, Vmax MasterScreen, and Micro Medical PFT instrumentation.
Features & Benefits
- 99.999% viral and bacterial efficiency against cross contamination (Nelson Test Report 10003754)
- Low resistance to airflow
- Minimal dead space (55mL)
- Filter housing and filter fleece tested for biocompatibility
- Three filter configuration versions, two package sizes
- Validated for compliance with the complete Vyaire Respiratory Diagnostics product line
MicroGard II B has an integrated oval shaped mouthpiece suitable for adult and pediatric use. The IIB kit includes an oval filter with nose clip.
MicroGard II C has a round shaped connector for use with special lung function mouthpieces, ideal for gas dilution and body plethysmographic measurements. The II C kit includes a round filter with nose clip and rubber mouthpiece.
Please note that all products, services, or features of products and services may not be available in your local area. Please check with your local Vyaire representative.
Extensive testing has been done on the MicroGard II filter. Nelson Laboratory testing shows that the MicroGard II filter offers the right balance between optimized filtration efficiency and minimal resistance to airflow. The MicroGard II filter protects the patient, operator and equipment from cross-contamination without affecting the equipment measurement characteristics.
The Latest News From Vyaire
“As the leading manufacturer of solutions for the treatment and monitoring of respiratory conditions at every stage of life, Vyaire Medical has been working tirelessly to deliver our ventilator equipment for patients in respiratory distress due to COVID-19, and to the healthcare workers treatingRead More
CHICAGO – April 3, 2020 – Vyaire Medical, Inc. and CEO Gaurav Agarwal today issued the following update on the company’s response to the coronavirus (COVID-19) pandemic:Read More